Drugs / Spikevax bivalent Original/Omicron BA.4-5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05075538 | Dec 2021 → Jan 2024 | cancer | Jules Bordet Institute | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spikevax bivalent Original/Omicron BA.4-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05075538 ↗ |